For oligometastatic NSCLC that would be otherwise considered stage 3, would you consider consolidative immunotherapy with durvalumab after definitive treatment for both the primary and oligometastatic site?  

This is an excellent question and timely in light of the greater numbers of patients being referred for "definitive treatment" of limited metastatic NSCLC. I fully agree with @Martin J. Edelman that there are multiple reasons/justification to offer these patients IO after their "definitive ther...

The occurrence of NSCLC defined by “stage III” disease in the chest, i.e. a primary lesion and mediastinal nodal involvement with an accompanying solitary metastasis elsewhere in the body (most typically another lobe of the lung, adrenal or brain) is a situation t...